Mesoblast Ltd. (NASDAQ:MESO) has been given a consensus recommendation of “Buy” by the six analysts that are covering the stock. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $8.63.
A number of equities analysts recently commented on the company. Zacks Investment Research upgraded Mesoblast from a “hold” rating to a “buy” rating and set a $5.50 price objective on the stock in a research report on Friday, September 2nd. Maxim Group reiterated a “buy” rating and set a $14.00 price objective on shares of Mesoblast in a research report on Wednesday, July 6th. Finally, Credit Suisse Group AG downgraded Mesoblast from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $10.00 to $5.00 in a research report on Tuesday, June 14th.
A number of large investors have recently bought and sold shares of the stock. Princeton Capital Management Inc. increased its stake in Mesoblast by 135.4% in the second quarter. Princeton Capital Management Inc. now owns 109,382 shares of the company’s stock worth $433,000 after buying an additional 62,915 shares in the last quarter. OLD Mission Capital LLC acquired a new stake in Mesoblast during the first quarter worth approximately $431,000. Citigroup Inc. increased its stake in Mesoblast by 659,900.0% in the second quarter. Citigroup Inc. now owns 33,000 shares of the company’s stock worth $131,000 after buying an additional 32,995 shares in the last quarter. Finally, Prudential PLC increased its stake in Mesoblast by 2.0% in the first quarter. Prudential PLC now owns 1,538,629 shares of the company’s stock worth $14,802,000 after buying an additional 29,597 shares in the last quarter. Institutional investors own 3.41% of the company’s stock.
Mesoblast (NASDAQ:MESO) opened at 4.44 on Wednesday. The company’s market cap is $335.55 million. Mesoblast has a 52-week low of $3.50 and a 52-week high of $13.00. The stock’s 50 day moving average price is $4.74 and its 200-day moving average price is $6.03.
Receive News & Ratings for Mesoblast Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.